Gutzmer, Ralf

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,839

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 1,906

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,039

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., et al. (2020) · The Lancet

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 663

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 589

Combined treatment with H1 and H4 receptor antagonists reduces inflammation in a mouse model of atopic dermatitis

Köchling, H., Schaper, K., Wilzopolski, J., Gutzmer, R., Werfel, T., Bäumer, W., Kietzmann, M., & Rossbach, K. (2017) · Journal of Dermatological Science

Dermatology and Skin DiseasesMast cells and histamine

Cited by 26

Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions

Eigentler, T. K., Schlaak, M., Hassel, J. C., Loquai, C., Stoffels, I., Gutzmer, R., Pätzold, S., Mohr, P., Keller, U., Starz, H., et al. (2014) · Journal of Immunotherapy

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 23